Sugi Predict

Sugi Predict / Compounds / SCHEMBL11968645

SCHEMBL11968645

SCHEMBL11968645

CN(C)C(=O)C(O)c1cncc(-c2cnc3[nH]cc(-c4ccc(C(F)(F)F)cc4)c3c2)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SGK1 O00141 6/20 0.49
▸ MAP3K11 Q16584 1/20 0.48
▸ AAK1 Q2M2I8 1/20 0.47
▸ CCNT1 O60563 1/20 0.46
▸ CCNA2 P20248 1/20 0.46
▸ CDK2 P24941 1/20 0.46
▸ CDK9 P50750 1/20 0.46
▸ PLCG1 P19174 1/20 0.46
▸ RIPK1 Q13546 2/20 0.44
▸ NTRK1 P04629 2/20 0.44
▸ ABL1 P00519 1/20 0.44
▸ CLK1 P49759 3/20 0.44
▸ DYRK1A Q13627 3/20 0.44
▸ DYRK2 Q92630 2/20 0.44
▸ DYRK1B Q9Y463 2/20 0.44
▸ AXL P30530 2/20 0.44
▸ CAMKK2 Q96RR4 2/20 0.44
▸ NEK1 Q96PY6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11968620 0.90 RIPK1 (0.55) CCNT1CCNA2CDK2CDK9RIPK1
SCHEMBL11968626 0.90 CLK1 (0.53) SGK1MAP3K11ABL1CLK1DYRK1A
SCHEMBL11968628 0.89 NTRK1 (0.56) MAP3K11PLCG1NTRK1ABL1AXL
SCHEMBL11968617 0.89 MAP3K11 (0.52) SGK1MAP3K11AAK1NTRK1ABL1
SCHEMBL11968631 0.88 CCNT1 (0.48) SGK1MAP3K11CCNT1CCNA2CDK2
SCHEMBL11968615 0.88 MAP3K11 (0.51) SGK1MAP3K11PLCG1NTRK1ABL1
SCHEMBL11968633 0.88 MAPK8 (0.54) SGK1MAP3K11NTRK1ABL1CLK1
SCHEMBL14041541 0.88 NTRK1 (0.55) SGK1MAP3K11NTRK1ABL1CLK1
SCHEMBL11968623 0.88 SGK1 (0.56) SGK1MAP3K11CDK2NTRK1ABL1
SCHEMBL11968629 0.87 MAP3K11 (0.50) SGK1MAP3K11PLCG1NTRK1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242280-B2 morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia SGX PHARMACEUTICALS, INC. (US) 2012-08-14 — — US disclosed
US-8242280-B2 morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia SGX PHARMACEUTICALS, INC. (US) 2012-08-14 — — US disclosed
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS MAP3K20, MAP3K19, MAP4K2 SGK1 323/4885MAP3K11 18/4885AAK1 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.